Ionis Pharmaceuticals, Inc.
IONS · NASDAQ
10/28/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $156,719 | $452,049 | $131,612 | $226,576 |
| % Growth | -65.3% | 243.5% | -41.9% | – |
| Cost of Goods Sold | $2,338 | $4,151 | $1,500 | $3,830 |
| Gross Profit | $154,381 | $447,898 | $130,112 | $222,746 |
| % Margin | 98.5% | 99.1% | 98.9% | 98.3% |
| R&D Expenses | $258,875 | $217,460 | $200,759 | $245,490 |
| G&A Expenses | $96,800 | $90,600 | $76,300 | $88,100 |
| SG&A Expenses | $96,809 | $90,600 | $76,300 | $88,100 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$41,121 | $22 | -$87 | -$21 |
| Operating Expenses | $314,563 | $308,082 | $276,972 | $333,569 |
| Operating Income | -$160,182 | $139,816 | -$146,860 | -$110,823 |
| % Margin | -102.2% | 30.9% | -111.6% | -48.9% |
| Other Income/Exp. Net | $31,789 | -$16,285 | $38 | $3,784 |
| Pre-Tax Income | -$128,393 | $123,531 | -$146,822 | -$107,039 |
| Tax Expense | $213 | -$20 | $116 | -$2,690 |
| Net Income | -$128,606 | $123,551 | -$146,938 | -$104,349 |
| % Margin | -82.1% | 27.3% | -111.6% | -46.1% |
| EPS | -0.8 | 0.78 | -0.93 | -0.66 |
| % Growth | -202.6% | 183.9% | -40.9% | – |
| EPS Diluted | -0.8 | 0.68 | -0.93 | -0.66 |
| Weighted Avg Shares Out | 160,758 | 159,137 | 158,735 | 158,000 |
| Weighted Avg Shares Out Dil | 160,758 | 182,331 | 158,735 | 158,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $23,682 | $24,687 | $24,667 | $28,910 |
| Interest Expense | $22,164 | $22,762 | $22,930 | $22,860 |
| Depreciation & Amortization | $11,851 | $5,454 | $5,397 | $5,267 |
| EBITDA | -$94,378 | $150,233 | -$120,003 | -$80,503 |
| % Margin | -60.2% | 33.2% | -91.2% | -35.5% |